Reviewing Progenics Pharmaceuticals Inc. (PGNX)’s and CytomX Therapeutics Inc. (NASDAQ:CTMX)’s results

Both Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) and CytomX Therapeutics Inc. (NASDAQ:CTMX) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Progenics Pharmaceuticals Inc. 5 -0.02 68.58M -0.90 0.00
CytomX Therapeutics Inc. 6 3.50 41.13M -1.91 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.


Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Progenics Pharmaceuticals Inc. 1,274,721,189.59% -80.6% -44.3%
CytomX Therapeutics Inc. 669,869,706.84% -73.6% -18.9%

Risk & Volatility

Progenics Pharmaceuticals Inc. has a 2.7 beta, while its volatility is 170.00% which is more volatile than S&P 500. CytomX Therapeutics Inc. has a 0.6 beta and it is 40.00% less volatile than S&P 500.


Progenics Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 4.8 and 4.8 respectively. The Current Ratio and Quick Ratio of its competitor CytomX Therapeutics Inc. are 4.2 and 4.2 respectively. Progenics Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to CytomX Therapeutics Inc.

Analyst Recommendations

The next table highlights the given recommendations and ratings for Progenics Pharmaceuticals Inc. and CytomX Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Progenics Pharmaceuticals Inc. 0 0 1 3.00
CytomX Therapeutics Inc. 0 1 1 2.50

Progenics Pharmaceuticals Inc.’s upside potential currently stands at 99.60% and an $10 consensus target price. Competitively CytomX Therapeutics Inc. has an average target price of $12, with potential upside of 84.33%. Based on the data given earlier, Progenics Pharmaceuticals Inc. is looking more favorable than CytomX Therapeutics Inc., analysts view.

Institutional and Insider Ownership

Progenics Pharmaceuticals Inc. and CytomX Therapeutics Inc. has shares owned by institutional investors as follows: 80.3% and 84.7%. Insiders owned roughly 0.1% of Progenics Pharmaceuticals Inc.’s shares. Insiders Comparatively, owned 0.7% of CytomX Therapeutics Inc. shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Progenics Pharmaceuticals Inc. 2.09% -9.73% 7.82% 19.56% -35.26% 28.1%
CytomX Therapeutics Inc. 1.78% -9.16% 10.27% -38.41% -58.88% -31.72%

For the past year Progenics Pharmaceuticals Inc. had bullish trend while CytomX Therapeutics Inc. had bearish trend.


On 8 of the 12 factors Progenics Pharmaceuticals Inc. beats CytomX Therapeutics Inc.

Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The companyÂ’s primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant and/or recurrent pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer. Its clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and EXINI bone BSI range of prostate cancer bone scan indexing products. The company also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness adult patients receiving palliative care when laxative therapy has not been sufficient, as well as for treatment of OIC in patients with non-cancer pain; and Relistor-oral tablets for the treatment of OIC. The company has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA, as well as has collaboration agreement with Seattle Genetics, Inc. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York, New York.

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, comprising CD-166. Its other product candidates in preclinical development include CX-2029, CD71, CTLA-4, and CX-188. In addition, the company has strategic collaborations with AbbVie Ireland Unlimited Company, Bristol-Myers Squibb Company, ImmunoGen, Inc., M D Anderson Cancer Center, Pfizer Inc., and The University of Texas to develop Probody therapeutics. It also has a strategic collaboration with Amgen Inc. to co-develop a CytomX Probody T-cell engaging bispecific against the epidermal growth factor receptor, a validated oncology target expressed on multiple human cancer types. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.